SUBSCRIBE
SUBSCRIBE

Blue Earth Therapeutics

IN THE PRESS
Press Releases
Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC
October 7, 2025
 · 
5 min read
Press Releases
Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
June 25, 2025
 · 
5 min read
Press Releases
Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer
May 1, 2025
 · 
5 min read
Press Releases
Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
March 13, 2025
 · 
6 min read
Press Releases
Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies
October 30, 2024
 · 
5 min read
Press Releases
Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data
October 8, 2024
 · 
5 min read
Business
SHINE Technologies Partners with Blue Earth Therapeutics for First Supply of Ilumira from Its New Facility
June 6, 2024
 · 
3 min read
Pharm Country
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
April 8, 2024
 · 
7 min read
Pharm Country
Blue Earth Therapeutics Announces Participation in Upcoming B. Riley Securities Radiopharma Investor Conference
February 28, 2024
 · 
3 min read
Pharm Country
Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer
February 20, 2024
 · 
5 min read
Load More
JOBS